Diagnosis and Treatment > Investigation > Testosterone
You are looking at 51 - 60 of 72 items
Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
Search for other papers by Emilia Sbardella in
Google Scholar
PubMed
Search for other papers by George Farah in
Google Scholar
PubMed
Search for other papers by Ahmed Fathelrahman in
Google Scholar
PubMed
Search for other papers by Simon Cudlip in
Google Scholar
PubMed
Search for other papers by Olaf Ansorge in
Google Scholar
PubMed
Search for other papers by Niki Karavitaki in
Google Scholar
PubMed
Search for other papers by Ashley B Grossman in
Google Scholar
PubMed
Summary
Pituitary adenomas are a common intracranial neoplasm, usually demonstrating a benign phenotype. They can be classified according to pathological, radiological or clinical behaviour as typical, atypical or carcinomas, invasive or noninvasive, and aggressive or nonaggressive. Prolactinomas account for 40–60% of all pituitary adenomas, with dopamine agonists representing the first-line treatment and surgery/radiotherapy reserved for drug intolerance/resistance or in neuro-ophthalmological emergencies. We present the case of a 62-year-old man with an apparently indolent prolactin-secreting macroadenoma managed with partial resection and initially showing a biochemical response to cabergoline. Five years later, the tumour became resistant to cabergoline, despite a substantial increase in dosage, showing rapid growth and causing worsening of vision. The patient then underwent two further transsphenoidal operations and continued on high-dose cabergoline; despite these interventions, the tumour continued enlarging and prolactin increased to 107 269 U/L. Histology of the third surgical specimen demonstrated features of aggressive behaviour (atypical adenoma with a high cell proliferation index) not present in the tumour removed at the first operation. Subsequently, he was referred for radiotherapy aiming to control tumour growth.
Learning points:
-
The development of secondary resistance to dopamine agonists (DAs) is a serious sign as it may be associated with de-differentiation of the prolactinoma and thus of aggressive or malignant transformation.
-
Significant de-differentiation of the adenoma documented on consecutive histologies suggests a possible transition to malignancy.
-
A combination of histological ‘alarm’ features associated with persistent growth and escape from DAs treatment in recurrent adenomas should alert clinicians and demands close follow-up.
-
A multidisciplinary approach by pathologists, endocrinologists and neurosurgeons is essential.
Search for other papers by Fergus Keane in
Google Scholar
PubMed
School of Medicine, National University of Ireland Galway, Newcastle, Galway, Ireland
Search for other papers by Aoife M Egan in
Google Scholar
PubMed
Search for other papers by Patrick Navin in
Google Scholar
PubMed
Search for other papers by Francesca Brett in
Google Scholar
PubMed
School of Medicine, National University of Ireland Galway, Newcastle, Galway, Ireland
Search for other papers by Michael C Dennedy in
Google Scholar
PubMed
Summary
Pituitary apoplexy represents an uncommon endocrine emergency with potentially life-threatening consequences. Drug-induced pituitary apoplexy is a rare but important consideration when evaluating patients with this presentation. We describe an unusual case of a patient with a known pituitary macroadenoma presenting with acute-onset third nerve palsy and headache secondary to tumour enlargement and apoplexy. This followed gonadotropin-releasing hormone (GNRH) agonist therapy used to treat metastatic prostate carcinoma. Following acute management, the patient underwent transphenoidal debulking of his pituitary gland with resolution of his third nerve palsy. Subsequent retrospective data interpretation revealed that this had been a secretory gonadotropinoma and GNRH agonist therapy resulted in raised gonadotropins and testosterone. Hence, further management of his prostate carcinoma required GNRH antagonist therapy and external beam radiotherapy. This case demonstrates an uncommon complication of GNRH agonist therapy in the setting of a pituitary macroadenoma. It also highlights the importance of careful, serial data interpretation in patients with pituitary adenomas. Finally, this case presents a unique insight into the challenges of managing a hormonal-dependent prostate cancer in a patient with a secretory pituitary tumour.
Learning points
-
While non-functioning gonadotropinomas represent the most common form of pituitary macroadenoma, functioning gonadotropinomas are exceedingly rare.
-
Acute tumour enlargement, with potential pituitary apoplexy, is a rare but important adverse effect arising from GNRH agonist therapy in the presence of both functioning and non-functioning pituitary gonadotropinomas.
-
GNRH antagonist therapy represents an alternative treatment option for patients with hormonal therapy-requiring prostate cancer, who also have diagnosed with a pituitary gonadotropinoma.
Search for other papers by Ahmed Iqbal in
Google Scholar
PubMed
Search for other papers by Peter Novodvorsky in
Google Scholar
PubMed
Search for other papers by Alexandra Lubina-Solomon in
Google Scholar
PubMed
Search for other papers by Fiona M Kew in
Google Scholar
PubMed
Search for other papers by Jonathan Webster in
Google Scholar
PubMed
Summary
Secondary amenorrhoea and galactorrhoea represent a common endocrine presentation. We report a case of an oestrogen-producing juvenile granulosa cell tumour (JGCT) of the ovary in a 16-year-old post-pubertal woman with hyperprolactinaemia amenorrhoea and galactorrhoea which resolved following surgical resection of the tumour. This patient presented with a 9-month history of secondary amenorrhoea and a 2-month history of galactorrhoea. Elevated serum prolactin at 7081 mIU/l and suppressed gonadotropins (LH <0.1 U/l; FSH <0.1 U/l) were detected. Serum oestradiol was significantly elevated at 7442 pmol/l with undetectable β-human chorionic gonadotropin. MRI showed a bulky pituitary with no visible adenoma. MRI of the abdomen showed a 4.8 cm mass arising from the right ovary with no evidence of metastatic disease. Serum inhibin B was elevated at 2735 ng/l. A right salpingo-oophorectomy was performed, and histology confirmed the diagnosis of a JGCT, stage International Federation of Gynaecology and Obstetrics 1A. Immunohistochemical staining for prolactin was negative. Post-operatively, oestrogen and prolactin levels were normalised, and she subsequently had a successful pregnancy. In summary, we present a case of an oestrogen-secreting JGCT with hyperprolactinaemia manifesting clinically with galactorrhoea and secondary amenorrhoea. We postulate that observed hyperprolactinaemia was caused by oestrogenic stimulation of pituitary lactotroph cells, a biochemical state analogous to pregnancy. To the best of our knowledge, this is the first report of hyperprolactinaemia as a result of excessive oestrogen production in the context of a JGCT.
Learning points
-
Hyperprolactinaemia with bilateral galactorrhoea and secondary amenorrhoea has a wide differential diagnosis and is not always caused by a prolactin secreting pituitary adenoma.
-
Significantly elevated serum oestradiol levels in the range seen in this case, in the absence of pregnancy, are indicative of an oestrogen-secreting tumour.
-
JGCTs are rare hormonally active ovarian neoplasms mostly secreting steroid hormones.
-
Serum inhibin can be used as a granulosa cell-specific tumour marker.
-
JGCTs have an excellent prognosis in the early stages of the disease.
Search for other papers by J Bukowczan in
Google Scholar
PubMed
Search for other papers by K Lois in
Google Scholar
PubMed
Search for other papers by M Mathiopoulou in
Google Scholar
PubMed
Search for other papers by A B Grossman in
Google Scholar
PubMed
Search for other papers by R A James in
Google Scholar
PubMed
Summary
Giant prolactinomas are rare tumours of the pituitary, which typically exceed 40 mm in their largest dimension. Impairment of higher cognitive function has been noted post-operatively after transcranial surgery and as a long-term consequence of the radiotherapy treatment. However, there has been little that is reported on such disturbances in relation to the tumour per se, and to our knowledge, there has been none in terms of responsivity to dopamine agonist therapy and shrinkage in these tumours. We present a case of successful restoration of severely impaired cognitive functions achieved safely after significant adenoma involution with medical treatment alone.
Learning points
-
Giant prolactinomas can be present with profound cognitive defects.
-
Dopamine agonists remain in the mainstay first-line treatment of giant prolactinomas.
-
Mechanisms of the reversible cognitive impairment associated with giant prolactinoma treatment appear to be complex and remain open to further studies.
-
Young patients with giant prolactinomas mandate genetic testing towards familial predisposition.
Search for other papers by J Rajkanna in
Google Scholar
PubMed
Search for other papers by S Tariq in
Google Scholar
PubMed
Search for other papers by S O Oyibo in
Google Scholar
PubMed
Summary
Gonadotrophin therapy with human chorionic gonadotrophin and recombinant FSH is indicated for use in men with reduced spermatogenesis due to hypogonadotrophic hypogonadism (HH). Patients require regular monitoring for side effects and desired response to treatment. We present a man with HH, azoospermia and a history of previous anabolic steroid usage who had undergone gonadotrophin therapy, had subsequently achieved conception and has now fathered a child.
Learning points
-
In total, 15% of couples do not achieve pregnancy within 1 year and seek medical treatment for infertility: male factors contribute to 50% of these.
-
The evaluation of male infertility should include a full history and examination, an endocrine profile and a quality-controlled semen analysis.
-
HH with defective spermatogenesis is an important cause of male infertility in a small percentage of cases.
-
Gonadotrophin therapy requires regular monitoring for side effects and desired response to treatment.
-
Any sustained rise in prostate specific antigen levels should prompt urological assessment for possible prostate biopsy.
-
A multidisciplinary approach is required for gonadotrophin therapy, especially if assisted fertilisation techniques are required once, spermatogenesis is achieved.
Search for other papers by Rossella Mazzilli in
Google Scholar
PubMed
Search for other papers by Michele Delfino in
Google Scholar
PubMed
Search for other papers by Jlenia Elia in
Google Scholar
PubMed
Search for other papers by Francesco Benedetti in
Google Scholar
PubMed
Search for other papers by Laura Alesi in
Google Scholar
PubMed
Search for other papers by Luciana Chessa in
Google Scholar
PubMed
Search for other papers by Fernando Mazzilli in
Google Scholar
PubMed
Summary
We report the case of a 19-year-old boy, presenting several congenital malformations (facial dysmorphisms, cardiac and musculoskeletal abnormalities), mental retardation, recurrent respiratory infections during growth and delayed puberty. Although previously hospitalised in other medical centres, only psychological support had been recommended for this patient. In our department, genetic, biochemical/hormonal and ultrasound examinations were undertaken. The karyotype was 49,XXXXY, a rare aneuploidy with an incidence of 1/85 000–100 000, characterised by the presence of three extra X chromosomes in phenotypically male subjects. The hormonal/biochemical profile showed hypergonadotropic hypogonadism, insulin resistance and vitamin D deficiency. The patient was then treated with testosterone replacement therapy. After 12 months of treatment, we observed the normalisation of testosterone levels. There was also an increase in pubic hair growth, testicular volume and penis size, weight loss, homeostatic model assessment index reduction and the normalisation of vitamin D values. Moreover, the patient showed greater interaction with the social environment and context.
Learning points
-
In cases of plurimalformative syndrome, cognitive impairment, recurrent infections during growth and, primarily, delayed puberty, it is necessary to ascertain as soon as possible whether the patient is suffering from hypogonadism or metabolic disorders due to genetic causes. In our case, the diagnosis of hypogonadism, and then of 49,XXXXY syndrome, was unfortunately made only at the age of 19 years.
-
The testosterone replacement treatment, even though delayed, induced positive effects on: i) development of the reproductive system, ii) regulation of the metabolic profile and iii) interaction with the social environment and context.
-
However, earlier and timely hormonal replacement treatment could probably have improved the quality of life of this subject and his family.
Search for other papers by Asma Deeb in
Google Scholar
PubMed
Search for other papers by Hana Al Suwaidi in
Google Scholar
PubMed
Search for other papers by Salima Attia in
Google Scholar
PubMed
Search for other papers by Ahlam Al Ameri in
Google Scholar
PubMed
Summary
Combined17α-hydroxylase/17,20-lyase deficiency is a rare cause of congenital adrenal hyperplasia and hypogonadism. Hypertension and hypokalemia are essential presenting features. We report an Arab family with four affected XX siblings. The eldest presented with abdominal pain and was diagnosed with a retroperitoneal malignant mixed germ cell tumour. She was hypertensive and hypogonadal. One sibling presented with headache due to hypertension while the other two siblings were diagnosed with hypertension on a routine school check. A homozygous R96Q missense mutation in P450c17 was detected in the index case who had primary amenorrhea and lack of secondary sexual characters at 17 years. The middle two siblings were identical twins and had no secondary sexual characters at the age of 14. All siblings had hypokalemia, very low level of adrenal androgens, high ACTH and high levels of aldosterone substrates. Treatment was commenced with steroid replacement and puberty induction with estradiol. The index case had surgical tumor resection and chemotherapy. All siblings required antihypertensive treatment and the oldest remained on two antihypertensive medications 12 years after diagnosis. Her breast development remained poor despite adequate hormonal replacement. Combined 17α-hydroxylase/17,20-lyase deficiency is a rare condition but might be underdiagnosed. It should be considered in young patients presenting with hypertension, particularly if there is a family history of consanguinity and with more than one affected sibling. Antihypertensive medication might continue to be required despite adequate steroid replacement. Breast development may remain poor in mutations causing complete form of the disease.
Learning points
-
Endocrine hypertension due to rarer forms of CAH should be considered in children and adolescents, particularly if more than one sibling is affected and in the presence of consanguinity.
-
17α-hydroxylase/17,20-lyase deficiency is a rare form of CAH but might be underdiagnosed.
-
Blood pressure measurement should be carried out in all females presenting with hypogonadism.
-
Anti-hypertensive medications might be required despite adequate steroid replacement.
-
Initial presenting features might vary within affected members of the same family.
-
Adverse breast development might be seen in the complete enzyme deficiency forms of the disease.
Search for other papers by Maura Bucciarelli in
Google Scholar
PubMed
Search for other papers by Ya-Yu Lee in
Google Scholar
PubMed
Search for other papers by Vasudev Magaji in
Google Scholar
PubMed
Summary
Ectopic ACTH secretion from breast cancer is extremely rare. We report a case of a 30-year-old woman with a history of breast cancer, who presented with psychosis and paranoid behaviour. CT of the head showed white matter disease consistent with posterior reversible encephalopathy syndrome (PRES). Despite using mifepristone with multiple antihypertensives including lisinopril, spironolactone and metoprolol, she was hypertensive. Transaminitis did not allow mifepristone dose escalation and ketoconazole utilization. Etomidate infusion at a non-sedating dose in the intensive care unit controlled her hypertension and cortisol levels. She was transitioned to metyrapone and spironolactone. She was discharged from the hospital on metyrapone with spironolactone and underwent chemotherapy. She died 9 months later after she rapidly redeveloped Cushing's syndrome and had progressive metastatic breast cancer involving multiple bones, liver and lungs causing respiratory failure.
Learning points
-
Cushing's syndrome from ectopic ACTH secreting breast cancer is extremely rare.
-
Cushing's syndrome causing psychosis could be multifactorial including hypercortisolism and PRES.
-
Etomidate at non-sedating doses in intensive care setting can be effective to reduce cortisol production followed by transition to oral metyrapone.
Search for other papers by Chrisanthi Marakaki in
Google Scholar
PubMed
Search for other papers by Anna Papadopoulou in
Google Scholar
PubMed
Search for other papers by Olga Karapanou in
Google Scholar
PubMed
Search for other papers by Dimitrios T Papadimitriou in
Google Scholar
PubMed
Search for other papers by Kleanthis Kleanthous in
Google Scholar
PubMed
Search for other papers by Anastasios Papadimitriou in
Google Scholar
PubMed
Summary
11β-hydroxylase deficiency (11β-OHD), an autosomal recessive inherited disorder, accounts for 5–8% of congenital adrenal hyperplasia. In Greece, no cases of 11β-OHD have been described so far. The patient presented at the age of 13 months with mild virilization of external genitalia and pubic hair development since the age of 3 months. Hormonal profile showed elevated 11-deoxycortisol, adrenal androgens and ACTH levels. ACTH stimulation test was compatible with 11β-OHD. DNA of the proband and her parents was isolated and genotyped for CYP11B1 gene coding cytochrome P450c11. The girl was found to be compound heterozygous for two CYP11B1 novel mutations, p.Ala386Glu (exon 7), inherited from the father and p.Leu471Argin (exon 9) from the mother. Hydrocortisone supplementation therapy was initiated. Four years after presentation she remains normotensive, her growth pattern is normal and the bone age remains advanced despite adequate suppression of adrenal androgens.
Learning points
-
11β-hydroxylase (CYP11B1) deficiency (11OHD; OMIM +202010) is the second most common cause of CAH accounting for approximately 5–8% of cases with an incidence of 1:100 000–1:200 000 live births in non-consanguineous populations.
-
Two CYP11B1 inactivating novel mutations, p.Ala386Glu and p.Leu471Arg are reported
-
Regarding newborn females, in utero androgen excess results in ambiguous genitalia, whereas in the male newborn diagnosis may go undetected. In infancy and childhood adrenal androgen overproduction results in peripheral precocious puberty in boys and various degrees of virilization in girls.
-
Accumulation of 11-deoxycorticosterone and its metabolites causes hypertension in about two thirds of patients.
-
Diagnosis lies upon elevated 11-deoxycortisol and DOC plus upstream precursors, such as 17α-hydroxyprogesterone and Δ4-androstenedione.
-
The established treatment of steroid 11β-OHD is similar to that of steroid 21-hydroxylase deficiency and consists of glucocorticoid administration in order to reduce ACTH-driven DOC overproduction resulting in hypertension remission and improvement of the virilization symptoms.
Search for other papers by Anita Kuriya in
Google Scholar
PubMed
Search for other papers by David V Morris in
Google Scholar
PubMed
Search for other papers by Michael H Dahan in
Google Scholar
PubMed
Summary
Cerebral vascular accidents are caused by vasospasm when induced by preeclampsia or by dopamine agonists. However, six arteries nourish the pituitary and prevent against vasospasm-induced damage, which up until now has not been thought to occur. Bromocriptine was used to arrest lactation in a 31-year-old with secondary amenorrhea following preeclampsia and fetal demise at 28 weeks gestation. Tests and history revealed panhypopituitarism not associated with hemorrhage or mass infarction but instead caused by vasospasm. The present study is the first report of pituitary damage from a non-hemorrhagic, vaso-occlusive event in the literature. In keeping with Sheehan's and Simon's syndromes, we have named pituitary damage resulting from vaso-occlusion as Dahan's syndrome, and a literature review suggests that it may be a common and previously overlooked disorder.
Learning points
-
Vasospasm can cause damage to the pituitary gland, although it was not previously believed to do so.
-
Preeclampsia and the use of a dopamine agonist, particularly in the peripartum state, may trigger vasospasm.
-
Vasospasm resulting from dopamine agonists may be a common cause of injury to the pituitary gland, and it may have been overlooked in the past.